key: cord-0428524-gdetjys2
authors: Eccles, J. A.; Thompson, B.; Themelis, K.; Amato, M.; Stocks, R.; Pound, A.; Jones, A.-M.; Cipinova, Z.; Shah-goodwin, L.; Timeyin, J.; Thompson, C. R.; Batty, T.; Harrison, N. A.; Critchley, H. D.; Davies, K.
title: BEYOND BONES - THE RELEVANCE OF VARIANTS OF CONNECTIVE TISSUE (HYPERMOBILITY) TO FIBROMYALGIA, ME/CFS AND CONTROVERSIES SURROUNDING DIAGNOSTIC CLASSIFICATION: AN OBSERVATIONAL STUDY
date: 2020-02-23
journal: nan
DOI: 10.1101/2020.02.21.20025072
sha: 168c7866538af3254e4c2d760b1cbd673dc8f575
doc_id: 428524
cord_uid: gdetjys2

Objectives: To understand the relevance of symptomatic hypermobility and related connective tissue variants to the expression of symptoms in Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study further tested if specific subfactors within the diagnostic classification of hypermobility predict clinical presentations. Design: We report part of a larger case-control study exploring mechanisms of chronic pain and fatigue in Fibromyalgia and ME/CFS (https://doi.org/10.1186/ISRCTN78820481) Setting: an NHS Clinical Research Facility. Participants: A subsample of 87 participants were assessed for symptomatic hypermobility by a trained clinician; 63 presented with a clinical diagnosis of either Fibromyalgia and or ME/CFS confirmed at screening; 24 participants were confirmed as healthy controls. Main outcome measures: 1) Brighton Criteria for joint hypermobility syndrome and 2017 hEDS diagnostic criteria. 2) ACR 2010 Diagnostic Criteria for Fibromylagia and Canadian and Fukada diagnostic criteria for ME/CFS. 3) Self report measures of subjective pain, fatigue and interoceptive sensibility. Results: Twenty of the 63 patients (32%) presented with a clinical diagnosis of Fibromyalgia; 24 (38%) with a clinical diagnosis of ME/CFS and 19 (30%) with dual diagnoses of fibromyalgia and ME/CFS. After evaluation using clinical research tools, 56 patients (89%) met ACR diagnostic criteria for fibromyalgia; 59 (94%) Canadian Criteria for ME/CFS; and 61 (97%) Fukada Criteria for ME/CFS. After research evaluation 52 patients (85%) in fact met diagnostic criteria for Fibromyalgia and ME/CFS on all three sets of tools (ACR, Canadian, Fukada). In addition, 51 patients (81%) and 9 (37.5%) healthy controls met Brighton Criteria for joint hypermobility syndrome and 11 (18%) and 2 (8%) of patients and controls respectively, on the 2017 hEDS criteria. Of these patient participants with symptomatic hypermobility only 12 (23.5%) had received a prior diagnosis of hypermobility. Across all participants meeting Brighton Criteria, 13 (22%) also endorsed a hEDS diagnosis. Membership of the patient group was predicted by meeting the Brighton Criteria for joint hypermobility syndrome (p=<0.001, OR 7.08, 95% CI 2.50 to 20.00), but not by meeting the hEDS criteria. The historical, rather than current Beighton score correlated with; 1) total pain reported on the McGill Pain Questionnaire (short form), (r= 0.25, n= 73, p=0.03); 2) Widespread Pain Index (derived from ACR diagnostic criteria) (r=0.26, n= 86, p=0.01); 3) ACR symptom severity (r=0.27, n=85, p=0.01); 4) Fatigue Impact (r=0.29, n=56, p=0.28); and 5) interoceptive sensibility (r=0.30, n=56, p=0.02. Conclusions: Symptomatic joint hypermobility is relevant to symptoms and diagnosis in Fibromyalgia and ME/CFS. These conditions are poorly understood yet have a considerable impact on quality of life. Further work is needed to determine the prevalence of hEDS within the general population and define the critical clinical dimensions within symptomatic hypermobility. It is important to note the high rates of mis/underdiagnosis of symptomatic hypermobility in this group. Moreover, we need to clarify the role of variant connective tissue in dysautonomic and inflammatory mechanisms implicated in the expression of pain and fatigue in fibromyalgia and ME/CFS. Our observations have implications for diagnosis and treatment targets. Study registration: ISCRTN78820481

• Results -Twenty of the 63 patients (32%) presented with a clinical diagnosis of Fibromyalgia; 24 (38%) with a clinical diagnosis of ME/CFS and 19 (30%) with dual diagnoses of fibromyalgia and ME/CFS. After evaluation using clinical research tools, 56 patients (89%) met ACR diagnostic criteria for fibromyalgia; 59 (94%) Canadian Criteria for ME/CFS; and 61 (97%) Fukada Criteria for ME/CFS. After research evaluation 52 patients (85%) in fact met diagnostic criteria for Fibromyalgia and ME/CFS on all three sets of tools (ACR, Canadian, Fukada). In addition, 51 . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint patients (81%) and 9 (37.5%) healthy controls met Brighton Criteria for joint hypermobility syndrome and 11 (18%) and 2 (8%) of patients and controls respectively, on the 2017 hEDS criteria. Of these patient participants with symptomatic hypermobility only 12 (23.5%) had received a prior diagnosis of hypermobility.

Across all participants meeting Brighton Criteria, 13 (22%) also endorsed a hEDS diagnosis. Membership of the patient group was predicted by meeting the Brighton Criteria for joint hypermobility syndrome (p=<0.001, OR 7.08, 95%CI 2.50 -20.00), but not by meeting the hEDS criteria. The historical, rather than current Beighton score correlated with; 1) total pain reported on the McGill Pain Questionnaire (short form), (r= 0.25, n= 73, p=0.03); 2) Widespread Pain Index (derived from ACR diagnostic criteria) (r=0.26, n= 86, p=0.01); 3) ACR symptom severity (r=0.27, n=85, p=0.01); 4) Fatigue Impact (r=0.29, n=56, p=0.28); and 5) interoceptive sensibility (r=0.30, n=56, p=0.02).

• Conclusions -Symptomatic joint hypermobility is relevant to symptoms and diagnosis in Fibromyalgia and ME/CFS. These conditions are poorly understood yet have a considerable impact on quality of life. Further work is needed to determine the prevalence of hEDS within the general population and define the critical clinical dimensions within symptomatic hypermobility. It is important to note the high rates of mis/underdiagnosis of symptomatic hypermobility in this group. Moreover, we need to clarify the role of variant connective tissue in dysautonomic and inflammatory mechanisms implicated in the expression of pain and fatigue in fibromyalgia and ME/CFS. Our observations have implications for diagnosis and treatment targets.

• Study registration -ISCRTN78820481 . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint .

Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have overlapping symptoms. Fibromyalgia is a common, poorly understood, complex musculo-skeletal disorder that affects around 5% of the UK population 1 . It is polysymptomatic yet marked primarily by chronic widespread pain, typically believed to be non-inflammatory in nature. In addition, patients frequently report extramusculoskeletal symptoms, including both physical and emotional fatigue with subjective cognitive dysfunction ('fibrofog' 2 3 ). For quality of life, patients with fibromyalgia score significantly lower than the general population 2 , or patients with other musculo-skeletal disorders such as rheumatoid arthritis, osteoarthritis and SLE 4 , on all-eight health status domains. Pain, fatigue, subjective cognitive impairment and psychological disturbance (e.g. depression and anxiety) 5 have greatest impact on quality of life. Thus, pain and fatigue are identified as among the most disabling symptoms associated with fibromyalgia. Relatedly, pain is also frequently reported in ME/CFS 6 7 . Complexity to understanding their origins may have contributed at times to consideration of both fibromyalgia and ME/CFS as functional somatic, medically-unexplained, or somatisation disorders. The presence of shared symptoms in brain and body has also fuelled debate as to whether fibromyalgia and ME/CFS are manifestations of the same spectrum disorder or separate clinical entities 8 9 . Although the dominant symptom of fibromyalgia is pain and ME/CFS is disabling fatigue or post-exertional malaise, patients with either diagnosis typically experience pain (including hyperalgesia and central sensitisation), fatigue, sleep problems and cognitive difficulties 9 . Altered inflammatory markers 10 11 and dysautonomia 12-14 are reported in both fibromyalgia and ME/CFS, calling into question their perceived status as 'functional' disorders. Moreover, it is increasingly . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint recognized that fibromyalgia 15 and ME/CFS 5 16 17 are associated with joint hypermobility [18] [19] [20] [21] , an expression of variant connective tissue. In this context, most patients (82.6%) with Ehlers Danlos Syndrome -Hypermobility Type (EDS-HT) /Joint Hypermobility Syndrome patients (JHS) meet criteria for ME/CFS, compared to only 8.4% of controls 22 . Beighton (hypermobility) scores are higher in children with a ME/CFS diagnosis than gender-matched controls 23 . Similarly, criteria for joint hypermobility is reportedly met by 64.2% women with fibromyalgia compared to only 22% of controls 24 . Clinicians may diagnose hypermobility as fibromyalgia, since widespread pain is a key feature of both conditions 25 .

Joint hypermobility (including Ehlers-Danlos Syndrome(s)) 18-21 is common 26 27 and associated with many extra-articular features 28 . Internationally, there is little agreement on the precise definition of measurement and hypermobility, nor the point at which it constitutes a disorder. In 2017, a consensus group sought to re-classify Ehlers Danlos Syndrome-Hypermobility Type (EDS-HT). As a consequence, the terms hEDS (hypermobile EDS) and Hypermobility Spectrum Disorder (HSD) now refer to symptomatic joint hypermobility 29 . An earlier term, Joint Hypermobility Syndrome (diagnosed by Revised Brighton Criteria) 30 was made redundant and was previously deemed indistinquishable from EDS-HT 31 . However, one important distinction is that the Revised Brighton Criteria took into account historical joint hypermobility, whereas the newer criteria for hEDS rely on age and gender specific hypermobility cut-offs. A broader concept of a Hypermobility Spectrum Disorder (HSD) was introduced to describe the continuum that encompasses patients with symptomatic joint hypermobility through to people who do not meet full criteria for hEDS or related syndromes associated with joint hypermobility. However, this notion . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . of a spectrum also remains controversial. Since there are no genetic tests available for hEDS, a clinical diagnostic checklist is available and consistent with the 2017 consensus criteria 29 . Further research is required to validate clinical diagnostic criteria and international diagnostic codes, which presently are not consistent with newer nomenclature. In adults with hEDS/HSD, symptoms (including pain, fatigue, dysautonomic symptoms, co-ordination, attention/concentration deficits and quality of life in general) can be also classified according to severity, reflecting neither the old or new criteria for hEDS 32 . Debate regarding diagnostic classification has intensified following a report on the prevalence of EDS and JHS in primary care that suggests these diagnoses cannot be considered rare 33 . Moreover, symptomatic hypermobility has considerable impact on quality of life, at least comparable or greater than those with other rheumatological diseases. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] The morbidity of hEDS/HSD to patients is most commonly expressed as complaints to clinicians of chronic musculoskeletal pain, headache and fatigue. These symptoms impair physical activity and quality of life [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , common to both FIbromyalgia and ME/CFS. In rheumatology clinics, symptomatic hypermobility is estimated to contribute to nearly half of all outpatient appointments, but is only recognised 1 out of 19 times 46 . Under-diagnosis of hEDS/HDS may exacerbate potentially disabling symptoms complications 47 and comorbidities, including autonomic dysfunction 14 48 , fibromyalgia 24 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) 49 . Enhanced recognition of symptomatic hypermobility is essential to improve function and quality of life in a patient group, whose symptoms are typically poorly understood and frequently overlooked 46 . Accurate phenotyping of hEDS/HDS is needed for research, but it is also critical to effective . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint multi-disciplinary clinical management, from provision of accurate prognostic advice and identification of co-morbidity, to the offer of multi-professional support and delivery of effective therapies. The relevance extends beyond rheumatology to other clinical contexts; e.g. cardiology, paediatrics, neurology, gastroenterology, pain management and mental health settings.

The objective of this study was to understand the relevance of symptomatic hypermobility and related connective tissue variants to the expression of symptoms in Fibromyalgia ME/CFS. The study systematically tests associations between the diagnostic criteria for pain and fatigue symptom expression and further examines if specific sub factors within the diagnostic classifications of hypermobility predict clinical presentations.

This study is part of larger study investigating mechanisms of chronic pain and fatigue in fibromyalgia and ME/CFS (https://doi.org/10.1186/ISRCTN78820481) in adults. This paper focuses on the relevance of symptomatic hypermobility. All participants (patient participants and healthy controls) provided written informed consent and were compensated for their participation.

The study idea was formed after patients and prior research participants discussed . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint reviewed the study after funding was obtained and advised on the study protocol and design, strategies for recruitment reflecting their priorities, experiences and preferences. Patients and public assessed the burden of testing and the time required to participate in the study. Patients and public were involved in the promotion of the study through local support groups for patients living with fibromyalgia and ME/CFS. Patients and public will be involved in supporting the dissemination of the study findings to participants and wider relevant communities Patient participants with a clinical diagnosis of either fibromyalgia and/or ME/CFS were invited to be screened for the study. To be included in the study patients were required to either meet the American College of Rheumatology (ACR 2010) 50 diagnostic criteria for FM and/or both the Canadian 51 and Fukada (CDC) 52 Criteria for ME/CFS as assessed at screening. Patients were recruited by advertisement from local support organisations for Fibromyalgia and ME/CFS, local rheumatology clinics and via social media and bulletin boards. Inclusion criteria for healthy controls were as follows: A score no more than 3/10 on a pain visual analogue scale, a score of less than 36 on the Fatigue Severity Scale 53 and not meeting either the criteria for American ACR diagnostic criteria for fibromyalgia, or the Canadian and Fukada (CDC) Criteria for ME/CFS and be free of major psychiatric or neurological illness.

Healthy controls were also recruited via social media and bulletin boards. Neither patients nor controls were recruited/ selected or screened on the basis of hypermobility.

In total, 24 healthy controls were assessed alongside 63 patient participants. Where possible controls were matched to age and gender of patient participants.

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint All participants who responded to advertisements were provided with more information. If they were willing to continue, there were screened via telephone or via anonymized online questionnaires for eligibility. Consenting participants completed a series of baseline questionnaires measuring subjective pain (McGill Pain short form Questionnaire 54 ); fatigue (Fatigue Impact 55 , Modified Fatigue Impact Scale 56 ); brainfog (Mental Clutter Scale 57 ) and interoceptive sensibility 58 (Porges Body Perception Questionnaire 59 ). Demographic data was also collected and participants were assessed for presence of symptomatic hypermobility and variants of connective tissue by trained clinicians using the revised Brighton Criteria and the 2017 hEDS classification criteria 29 46 . It was not possible to determine the last item in criterion 2A

(Aortic root dilatation with Z-score >+2) as participants did not undergo echocardiography as part of the study protocol.

Each symptomatic hypermobility diagnostic classification (revised Brighton Criteria for JHS; hEDS 2017 consensus criteria) were entered as binary variables. Further binary variables explored categorical elements of the different criteria. The Beighton Scale and total number of major and minor criteria endorsed were expressed as scale data. Differences between groups in age and assessment outcomes were assessed via independent sample t tests. Differences in sex and associations between groups were assessed via chi square test. Binary logistic regression was used to derive prediction models for catergorical variables, their odds ratios and their confidence intervals where appropriate. Univariate analyses (General Linear Model) were used to determine interactions. Spearman correlations were used to explore . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.21.20025072 doi: medRxiv preprint correlations with Beighton score. Hypothesis tests were considered statistically significant for p-values < 0.05 and all analyses were carried out using SPSS version 25 for Mac.

Twenty-four healthy controls (9 male) and patients (12 male) did not differ . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.21.20025072 doi: medRxiv preprint

Beighton score Across all participants there were no associations between current (i.e. present) Beighton score and baseline pain, fatigue and interoceptive questionnaires.

Historical Beighton score (i.e ever being able to perform the relevant manoeuvre) 

Endorsing both major criteria of Brighton Criteria was significantly associated with an ACR fibromyalgia diagnosis( 2 6.53, p=0.01). ACR Fibromyalgia was associated with easy bruising, ( 2 7.58, p= 0.006). No other minor criteria were significantly predictive of fibromyalgia

Endorsing both major criteria of Brighton Criteria was significantly associated with fulfilling Canadian criteria for ME/CFS ( 2 7.64, p= 0.006), as was endorsing Fukada Criteria ( 2 10.50, p= 0.001). Easy bruising ( 2 4.22, p=0.040) was associated with both Canadian criteria for ME/CFS and Fukada Criteria ( 2 5.71 p= 0.017). No other minor criteria were significantly predictive of ME/CFS . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint The strength of this research study is that it is the first clinical evaluation to our knowledge, that incorporates and directly compares Brighton (Joint Hypermobility Syndrome) and hEDS criteria. This study demonstrates the overlapping nature of Fibromyalgia and ME/CFS within current diagnostic criteria, which remains controversial 8 9 . We show the contribution of symptomatic joint hypermobility and variants of connective tissue disorder to both conditions and to associated level of symptoms. Fibromyalgia and ME/CFS are both associated with inflammatory abnormalities 10 11 and dysautonomia 12-14 (e.g. orthostatic intolerance, postural orthostatic tachycardia syndrome and orthostatic hypotension), which is also commonly observed in symptomatic hypermobility 14 48 . In fact, autonomic dysfunction is proposed to mediate disabling symptoms in fibromyalgia and has an established association with variants of connective tissue and heightened interoceptive sensibility 60 . Interoceptive sensibility is subjective measurement of the sense relating to one's own internal bodily sensations 58 While it is clear that there are associations between symptomatic hypermobility and both fibromyalgia and ME/CFS, the relationships between these conditions remain poorly understood.

Ongoing research seeks to extend our observations reported here to determine how symptomatic hypermobility relates to autonomic and inflammatory induced changes in pain and fatigue in fibromyalgia and ME/CFS. Limitations of the present study include relatively small control group and difficulty in discriminating between painpredominant and fatigue-predominant disease. This paper adds further recognition to the high rates of hypermobility in fibromyalgia and ME/CFS. However, this is the first study to use multiple complementary assessments of joint hypermobility and variant connective tissue to explore these . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.21.20025072 doi: medRxiv preprint relationships. A rich debate has been stimulated by a recent paper reporting the prevalence of EDS and JHS 33 . While other forms of EDS are likely rare, the present study suggests hEDS is common among patients with pain and fatigue. Our control group is too small to make more than anecdotal statements regarding hEDS prevalence. However, approximately 1 in 5 of those meeting Brighton Criteria for joint hypermobility syndrome might endorse a diagnosis of hEDS and many patients appear to remain undiagnosed.

The classification of symptomatic joint hypermobility and variants of connective tissue is an evolving area 29 31 61 62 . Importantly, this study reveals that distinct aspects of the diagnostic criteria for symptomatic hypermobility predict symptom severity in pain and fatigue conditions. From these data, it would appear that the Brighton Criteria predict Fibromyalgia and ME/CFS diagnosis and symptomatology Interestingly, the Brighton Criteria make use of the historical account of joint laxity, which was highly associated with symptom severity, compared to current joint laxity, which is not included within the hEDS 2017 criteria (Criteria 1).

This relatively small study highlights the need for better recognition and accurate diagnosis in these poorly understood conditions. Fibromyalgia patients may wait on average almost a year after experiencing symptoms before presenting to a physician, and a diagnosis of fibromyalgia may take around 2.3 years, presenting to 3.7 different physicians, to be established 63 . Once confirmed a fibromyalgia diagnosis may have mixed benefits for patients 64 . Similar delays to diagnosis are observed for ME/CFS 65 . The impact on quality of life in Fibromyalgia and ME/CFS is severe 66 67 Greater awareness among the scientific and medical community about . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint the overlapping nature of these conditions and their system-wide symptomatology will improve the appropriate diagnosis and multi-disciplianry treatment for patients 68 .

Studies underway will determine the wider role of variant connective tissue (of which joint hypermobility may be but a single manifestation) in relationship to autonomic and inflammatory induced changes in pain and fatigue in Fibromyalgia and ME/CFS . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint The funder did not play a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The researchers are independent from the funders and all authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.21.20025072 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02. 21.20025072 doi: medRxiv preprint 

The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria

The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia

Fibrofog and fibromyalgia: a narrative review and implications for clinical practice

The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12

Patient perspectives on the impact of fibromyalgia

Mechanisms explaining muscle fatigue and muscle pain in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A review of recent findings

Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study

Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome

Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome

Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome

Need for a consensus on the methods by which to measure joint mobility and the definition of norms for hypermobility that reflect age, gender and ethnic-dependent variation: is revision of criteria for joint hypermobility syndrome and Ehlers-Danlos syndrome hypermobility type indicated?

Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature

author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint

Time to take hypermobility seriously (in adults and children)

Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome

Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls

Hypermobility in women with fibromyalgia syndrome

Pain management in the Ehlers-Danlos syndromes

Epidemiology of generalized joint laxity (hypermobility) in fourteen-year-old children from the UK: a population-based evaluation

Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey

Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations

A framework for the classification of joint hypermobility and related conditions

The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS)

The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome)

Severity classes in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders: a pilot study of 105 Italian patients

author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint

Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison

Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers-Danlos syndrome hypermobility type

Quality of life, unmet needs, and iatrogenic injuries in rehabilitation of patients with Ehlers-Danlos Syndrome hypermobility type/Joint Hypermobility Syndrome

Quality of life in the classic and hypermobility types of Ehlers-Danlos syndrome

Pain intensity and quality of life perception in children with hypermobility syndrome

Shoulder function, pain and health related quality of life in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome-hypermobility type

author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint

Generalised joint hypermobility and knee joint hypermobility: prevalence, knee joint symptoms and health-related quality of life in a Danish adult population

Generalised joint hypermobility and shoulder joint hypermobility, -risk of upper body musculoskeletal symptoms and reduced quality of life in the general population

Italian validation of the functional difficulties questionnaire (FDQ-9) and its correlation with major determinants of quality of life in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder

Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders

Quality of life prediction in children with joint hypermobility syndrome

Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers

author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint

Hypermobility in Adolescent Athletes: Pain, Functional Ability, Quality of Life, and Musculoskeletal Injuries

Hypermobility: an important but often neglected area within rheumatology

Neurological manifestations of Ehlers-Danlos syndrome(s): A review

Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome-Hypermobile type

Generalized joint hypermobility is more common in chronic fatigue syndrome than in healthy control subjects

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint

Dissociative experiences in fibromyalgia are mediated by symptoms of autonomic dysfunction

Contemporary approach to joint hypermobility and related disorders

Clinical Relevance of Joint Hypermobility and Its Impact on Musculoskeletal Pain and Bone Mass

A patient survey of the impact of fibromyalgia and the journey to diagnosis

The fibromyalgia diagnosis: hardly helpful for the patients? A qualitative focus group study

A national cross-sectional survey of diagnosed sufferers of myalgic encephalomyelitis/chronic fatigue syndrome: pathways to diagnosis, changes in quality of life and service priorities

The health-related quality of life for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

PloS one 2015;10(7):e0132421.. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.21. It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the

The copyright holder for this preprint